Drug Class Description
Antimetabolites (cytotoxics).
Generic Name
Generic
Drug Description
Solution for injection in Cytosafe polypropylene vials.
Presentation
Solution for injection, cytarabine 20mg/mL, 100mg/mL.
Indications
For induction of remission in acute myeloid leukaemia in adults and children.
Adult Dosage
By intravenous infusion or injection, or subcutaneous injection.
Child Dosage
Refer to Summary of Product Characteristics.
Contra Indications
Pre-existing drug-induced bone marrow suppression, unless clinician feels that such management offers most hopeful alternative for the patient. Should not be used in the management of non-malignant disease, except for immunosuppression. Should not normally be administered to patients who are pregnant or breastfeeding.
Special Precautions
Initiate therapy cautiously in pre-existing drug-induced bone marrow suppression; daily leucocyte and platelet counts required. Facilities should be available for management of complications, possibly fatal, of bone marrow suppression. Periodic monitoring of bone marrow, liver and kidney functions should be performed. May induce hyperuricaemia; monitor blood uric acid levels.
Interactions
5-fluorocytosine.
Adverse Reactions
Leucopenia, thrombocytopenia, anaemia, bone marrow suppression and megaloblastosis. Also, nausea, vomiting, diarrhoea, oral ulceration, hepatic dysfunction.
Manufacturer
Pharmacia & Upjohn
Drug Availability
(POM)
Updated
06 May 2009